S3751119th Congress
Prescription Drug Supply Chain Pricing Transparency Act
Sponsored By: Senator Bennet, Michael F. [D-CO]
Introduced
Summary
Requires a GAO study to bring transparency to price-related compensation structures across the retail prescription drug supply chain. It would direct the Comptroller General to examine how payment and fee arrangements are tied to a drug's price and whether those arrangements create conflicts of interest.
Show full summary
- Congress and policymakers: The Comptroller General must submit a GAO report within 2 years that includes findings and recommendations for legislation or administrative action.
- Intermediaries under review: The study would map the types, size, prevalence, and business models of price-based payments among PBMs, Part D plan sponsors, drug wholesalers, pharmacies, manufacturers, pharmacy services administrative organizations, brokers, auditors, consultants, rebate aggregators, and other service providers.
- Integrity and consumers: The study must assess potential conflicts, such as fees set as a percentage of a drug's price that may advantage higher-priced drugs. The report could inform future policy changes on formulary selection, distribution, or purchasing.
Your PRIA Score
Score Hidden
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
No Economic Impacts Identified for this Bill
Sponsors & CoSponsors
Sponsor
Bennet, Michael F. [D-CO]
CO • D
Cosponsors
Sen. Lankford, James [R-OK]
OK • R
Sponsored 1/29/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov